{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:19:59Z","timestamp":1791404399478,"version":"4.3.3"},"reference-count":94,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Multiple myeloma (MM), the second most common hematologic cancer, remains an incurable malignancy, characterized by an initial response to therapy followed by successive relapses. The upfront treatment typically involves induction therapy, autologous stem cell transplantation for eligible patients, and long-term maintenance therapy. It is important to note that the anticipated duration of myeloma response diminishes with each subsequent relapse. Therefore, the first relapse represents a critical juncture in treatment, where refractoriness to key drug classes emerges as a significant challenge. Addressing the optimal management in this setting requires careful consideration of disease biology, prior therapies, and patient-specific factors to optimize outcomes. Cilta-cel, a chimeric antigen receptor T-cell construct, has emerged as the most promising therapeutic option at first relapse, resulting in long-term remissions with a significant treatment-free interval. However, availability and accessibility are not universal and treatment logistics are complex. Triplet regimens based on carfilzomib, pomalidomide or selinexor, remain the cornerstone of treatment at first relapse, whereas the optimal combination is based on refractoriness to prior drugs, especially anti-CD38 monoclonal antibodies and lenalidomide, and patient comorbidities. With the rapidly expanding therapeutic landscape, clinicians face increasing complexity in selecting the most appropriate regimens for individual patients. This review aims to guide clinicians through these evolving options by consolidating evidence-based strategies and highlighting emerging therapies, ensuring a personalized approach to managing first-relapse MM.<\/jats:p>","DOI":"10.3390\/jcm14051655","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T06:45:42Z","timestamp":1740725142000},"page":"1655","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Current Treatment Strategies for Multiple Myeloma at First Relapse"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7731-610X","authenticated-orcid":false,"given":"Evangelos","family":"Mavrothalassitis","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Triantafyllakis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4673-171X","authenticated-orcid":false,"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2433-4753","authenticated-orcid":false,"given":"Martina","family":"Kleber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Clinic Hirslanden Zurich, 8032 Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Basel, 4031 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Padala, S.A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., and Ajebo, G.H. (2021). Epidemiology, Staging, and Management of Multiple Myeloma. Med. Sci., 9.","DOI":"10.3390\/medsci9010003"},{"key":"ref_2","first-page":"578","article-title":"Smoldering multiple myeloma: Pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies","volume":"12","author":"Kazandjian","year":"2014","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/asheducation-2013.1.478","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: Biological insights and early treatment strategies","volume":"2013","author":"Landgren","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2017.1.498","article-title":"Management of multiple myeloma in the newly diagnosed patient","volume":"2017","author":"Mateos","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Medina-Herrera, A., Sarasquete, M.E., Jim\u00e9nez, C., Puig, N., and Garc\u00eda-Sanz, R. (2023). Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future. Cancers, 15.","DOI":"10.3390\/cancers15143687"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","article-title":"Defining cure in multiple myeloma: A comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00277-020-04060-z","article-title":"Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: A single-center experience over 20-year period","volume":"99","author":"Terpos","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cam4.1283","article-title":"Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: Impact of clinical risk factors and sustained response","volume":"7","author":"Lehners","year":"2018","journal-title":"Cancer Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ajh.27582","article-title":"Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials","volume":"100","author":"Filippatos","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/ajh.27425","article-title":"Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group","volume":"99","author":"Katodritou","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: Recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1038\/s41375-018-0209-7","article-title":"European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias","volume":"32","author":"Gavriatopoulou","year":"2018","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.clml.2021.01.018","article-title":"Real-World Treatment of Patients with Relapsed\/Refractory Myeloma","volume":"21","author":"Gavriatopoulou","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"102051","DOI":"10.1016\/j.jgo.2024.102051","article-title":"Evaluating concordance between International Myeloma Working Group (IMWG) frailty score and simplified frailty scale among older adults with multiple myeloma","volume":"15","author":"Gahagan","year":"2024","journal-title":"J. Geriatr. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/hematology.2022000356","article-title":"The first relapse in multiple myeloma: How to pick the next best thing","volume":"2022","author":"Devarakonda","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"de Arriba de la Fuente, F., Montes Gais\u00e1n, C., and de la Rubia Comos, J. (2022). How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma. Cancers, 15.","DOI":"10.3390\/cancers15010155"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1182\/bloodadvances.2024012640","article-title":"Real-world treatment patterns and outcomes in relapsed\/refractory multiple myeloma (1-3 prior lines): Flatiron database","volume":"8","author":"Dhakal","year":"2024","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/bjh.19627","article-title":"Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence","volume":"205","author":"Weisel","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_26","unstructured":"Kastritis, E., Ntanasis-Stathopoulos, I., Theodorakakou, F., Migkou, M., Roussou, M., Malandrakis, P., Kanellias, N., Eleutherakis-Papaiakovou, E., Fotiou, D., and Spiliopoulou, V. (2025, February 21). Characteristics and Outcomes of Patients with Relapsed\/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece-PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/38616479\/."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall Survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","article-title":"Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR","volume":"20","author":"Mateos","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e1058","DOI":"10.1002\/jha2.1058","article-title":"Real-world characteristics and outcomes of patients with multiple myeloma receiving second-line treatment in England","volume":"6","author":"Moore","year":"2024","journal-title":"EJHaem"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e813","DOI":"10.1016\/S2352-3026(23)00218-1","article-title":"Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): Extended follow up of an open-label, randomised, multicentre, phase 3 trial","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: Updated results from IKEMA, a randomized Phase 3 study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/ejh.14314","article-title":"Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed\/Refractory Multiple Myeloma Patients","volume":"114","author":"Derudas","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41375-020-01021-3","article-title":"Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): Outcomes by prior treatment at first relapse","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Richardson, P., Beksa\u00e7, M., Oriol, A., Lindsay, J., Schjesvold, F., Galli, M., Ya\u011fc\u0131, M., Larocca, A., Weisel, K., and Yu, X. (2025). Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses from the Optimismm Trial. Eur. J. Haematol.","DOI":"10.1111\/ejh.14365"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kleber, M., Ntanasis-Stathopoulos, I., and Terpos, E. (2021). BCMA in Multiple Myeloma-A Promising Key to Therapy. J. Clin. Med., 10.","DOI":"10.3390\/jcm10184088"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"Dhakal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet Lond. Engl."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.clml.2023.07.013","article-title":"Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes","volume":"23","author":"Kastritis","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/s41375-020-0756-6","article-title":"Integrated safety profile of selinexor in multiple myeloma: Experience from 437 patients enrolled in clinical trials","volume":"34","author":"Gavriatopoulou","year":"2020","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): An interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Perrot, A., Touzeau, C., Lambert, J., Hulin, C., Caillot, D., Karlin, L., Arnulf, B., Rey, P., Garderet, L., and Macro, M. (2025). Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial. Blood, 2024026230.","DOI":"10.1182\/blood.2024026230"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Usmani, S.Z., Facon, T., Hungria, V., Bahlis, N.J., Venner, C.P., Braunstein, M., Pour, L., Mart\u00ed, J.M., Basu, S., and Cohen, Y.C. (2025). Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: The randomized phase 3 CEPHEUS trial. Nat. Med., 1\u20138.","DOI":"10.1038\/s41591-025-03581-2"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/S2352-3026(24)00347-8","article-title":"Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): A multicentre, single-arm, phase 2 trial","volume":"12","author":"Askeland","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ramasamy, K., Vij, R., Kuter, D., Cella, D., Durie, B.G.M., Abonour, R., Rifkin, R.M., Ailawadhi, S., Lee, H.C., and Cowan, A.J. (2024). Real-World Treatment Patterns and Clinical Outcomes in Patients with Multiple Myeloma Previously Treated with Lenalidomide and an Anti-CD38 Monoclonal Antibody. Clin. Lymphoma Myeloma Leuk.","DOI":"10.1016\/j.clml.2024.12.002"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: The AURIGA study","volume":"145","author":"Badros","year":"2025","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Mai, E.K., Bertsch, U., Pozek, E., Fenk, R., Besemer, B., Hanoun, C., Schroers, R., von Metzler, I., H\u00e4nel, M., and Mann, C. (2024). Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. J. Clin. Oncol.","DOI":"10.1200\/JCO-24-02266"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in Overall Survival with Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: Final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00277-020-03981-z","article-title":"Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma","volume":"99","author":"Terpos","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ajh.27206","article-title":"Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA","volume":"99","author":"Terpos","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/ajh.27382","article-title":"Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed\/refractory multiple myeloma","volume":"99","author":"Delimpasi","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Garcia-Gui\u00f1on, A., Charry, P.A., Jimenez, M., Sarra, J., Delgado, I., Segura de la Torre, L., Santaliestra, M., Garcia-Pintos, M., Gonzalez, Y., and Senin, A. (2025). Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed\/refractory multiple myeloma. Ann. Hematol., 1\u201310.","DOI":"10.1007\/s00277-025-06240-1"},{"key":"ref_62","first-page":"3681","article-title":"Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study","volume":"109","author":"Lee","year":"2024","journal-title":"Haematologica"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): Interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1182\/bloodadvances.2024013101","article-title":"A.R.R.O.W.2: Once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"8","author":"Dimopoulos","year":"2024","journal-title":"Blood Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","article-title":"American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol. Blood Marrow Transpl. Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/s41409-019-0590-5","article-title":"The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma","volume":"54","author":"Miller","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"E340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): A randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41375-020-0948-0","article-title":"Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide\/dexamethasone for relapsed multiple myeloma: The randomized GMMG phase III trial ReLApsE","volume":"35","author":"Goldschmidt","year":"2021","journal-title":"Leukemia"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41375-020-1005-8","article-title":"Salvage Second Transplantation in Relapsed Multiple Myeloma","volume":"35","author":"Dhakal","year":"2021","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbmt.2013.01.004","article-title":"Salvage Second Hematopoietic Cell Transplantation in Myeloma","volume":"19","author":"Michaelis","year":"2013","journal-title":"Biol. Blood Marrow Transpl. Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/bmt.2015.39","article-title":"Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT","volume":"50","author":"Nahi","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Hansen, D.K., Peres, L.C., Dima, D., Richards, A., Shune, L., Afrough, A., Midha, S., Dhakal, B., Kocoglu, M.H., and Atrash, S. (2025). Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed\/Refractory Multiple Myeloma. J. Clin. Oncol., JCO-24-01730.","DOI":"10.1016\/S2152-2650(24)01848-2"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e70070","DOI":"10.1002\/hem3.70070","article-title":"Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study","volume":"9","author":"Merz","year":"2025","journal-title":"HemaSphere"},{"key":"ref_74","first-page":"876","article-title":"Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma","volume":"30","author":"Wesson","year":"2024","journal-title":"Transpl. Transplant. Cell Ther."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Costa, L.J., Banerjee, R., Mian, H., Weisel, K., Bal, S., Derman, B.A., Htut, M.M., Nagarajan, C., Rodriguez, C., and Richter, J. (2025). International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia, 1\u201312.","DOI":"10.1038\/s41375-024-02482-6"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"New Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Kleber, M., Ntanasis-Stathopoulos, I., and Terpos, E. (2023). The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma. Cancers, 15.","DOI":"10.3390\/cancers15245829"},{"key":"ref_78","unstructured":"Pfizer (2024, December 18). MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People with Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment with an Anti-CD38 Antibody and Lenalidomide), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06152575."},{"key":"ref_79","unstructured":"Janssen Research (2024, December 18). Development, LLC. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05572515."},{"key":"ref_80","unstructured":"Janssen Research (2024, December 18). Development, LLC. A Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06208150."},{"key":"ref_81","unstructured":"Janssen Research (2024, December 29). Development, LLC. A Study Comparing Talquetamab in Combination with Daratumumab or in Combination with Daratumumab and Pomalidomide Versus Daratumumab in Combination with Pomalidomide and Dexamethasone in Participants with Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (MonumenTAL-3), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05455320."},{"key":"ref_82","unstructured":"Pfizer (2024, December 18). MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants with Relapsed\/Refractory Multiple Myeloma (MAGNETISMM-5), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05020236."},{"key":"ref_83","unstructured":"Janssen Research (2025, January 06). Development, LLC. A Study of Teclistamab in Combination with Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma (MajesTEC-3), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05083169."},{"key":"ref_84","unstructured":"Celgene (2025, January 04). A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06232707."},{"key":"ref_85","unstructured":"Regeneron Pharmaceuticals (2025, January 04). A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants with Relapsed\/Refractory Multiple Myeloma (LINKER-MM3), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05730036."},{"key":"ref_86","unstructured":"Celgene (2024, December 29). A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05519085."},{"key":"ref_87","unstructured":"Celgene (2024, December 29). Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04975997."},{"key":"ref_88","unstructured":"Bristol-Myers Squibb (2025, January 06). A Study to Evaluate Mezigdomide in Combination with Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05552976."},{"key":"ref_89","unstructured":"Kite, A Gilead Company (2025, January 06). A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants with Relapsed\/Refractory Multiple Myeloma (iMMagine-3), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06413498."},{"key":"ref_90","unstructured":"Nanjing IASO Biotechnology Co., Ltd. (2025, January 06). A Phase III Study of Eque-cel in Subjects with Len-refractory RRMM (FUMANBA-03) (FUMANBA-03), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06464991."},{"key":"ref_91","unstructured":"Biocad (2025, January 07). A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex\u00ae in Subjects with Relapsed and Refractory Multiple Myeloma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06296121."},{"key":"ref_92","unstructured":"Hangzhou Sumgen Biotech Co., Ltd. (2025, January 07). A Phase 3 Randomized, Placebo-controlled, Double-blind, Multicenter Study Comparing SG301 in Combination with Pomalidomide and Dexamethasone Versus Placebo in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06508983."},{"key":"ref_93","unstructured":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (2025, January 07). A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06615479."},{"key":"ref_94","unstructured":"Stichting European Myeloma Network (2025, January 04). A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05028348."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1655\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:44:36Z","timestamp":1760028276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":94,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051655"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051655","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]}}}